Pyoderma gangrenosum and IgA myeloma

Journal of Cutaneous Medicine and Surgery

Volumn 2, Issue 2, 1997, Pages 100-103

  Jackson, J Mark ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; IMMUNOGLOBULIN A; MELPHALAN; METRONIDAZOLE; PLASMA PROTEIN; PREDNISONE;

AGED; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; HUMAN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; PYODERMA GANGRENOSUM;

EID: 0031391603     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347549700200210     Document Type: Article

References (28)

1. Powell FC, Schroeter AL, Su WPD, et al. Pyoderma gangrenosum: a review of 86 patients. QJ Med 1985; 217:173-186.
2. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol 1930; 22: 655-680.
3. Perry HO, Brunsting LA. Pyoderma gangrenosum: a clinical study of 19 cases. Arch Dermatol 1957; 75:380-386.
4. Powell FC, Su DP, Perry HO. Pyoderma gangrenosum classification and management. J Am Acad Dermatol 1996; 34:395-409.
5. Callen JP, Taylor WB. Pyoderma gangrenosum - a review. Cutis 1978; 21:61-64.
6. Powell FC, Schroeter AL, Su WPD, et al. Pyoderma gangrenosum and monoclonal gammopathy. Arch Dermatol 1983; 119: 468-471.
7. Holt PJA, Davies MG, Saunders KC, et al. Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine 1980; 59:114-133.
8. van der Sluis I. Two cases of pyoderma (ecthyma) gangrenosum associated with the presence of an abnormal serum protein (beta 2A-paraprotein): with a review of the literature. Dermatologica 1966; 132:409-424.
9. Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Arch Dermatol 1989; 125:57-63.
10. Jablonska PS, Stachow A, Dabrowska H. Rapports entre la pyodermite gangreneuse et le myèlome. Ann Dermatol Syphiligr 1967; 94:121-132.
11. Thivelot J, Pellerat J, Hermier C, et al. Myelome avec agammaglobulinémie revelé par une pyodermite phagédenique. Lyon Med 1964; 212:107-112.
12. Rockl H, Knedel M, Schropl F. Über das Vorkommen von Paraproteinämie bei Pyoderma ulcerosa serpiginosa (Pyoderma gangraenosum - Dermatitis ulcerosa). Hautarzt 1964; 15:165-171.
13. Schallreuter KU. An uncommon onset of myeloma. J Am Acad Dermatol 1985; 13:819-821.
14. Sanchez YE, Cabre J. Pyoderma gangrenosum con mieloma IgA lambda y deficit de la inmunidad celular. Actas Dermo-Sifiliograficas 1980; 71:35-40.
15. Stone MS, Lyckholm LJ. Pyoderma gangrenosum and subcorneal pustular dermatosis: clues to underlying immunoglobulin A myeloma. Am J Med 1996; 100:663-664.
16. Kois JM, Sexton FM, Lookingbill DP. Cutaneous manifestations of multiple myeloma. Arch Dermatol 1991; 127:69-74.
17. Horton JJ, Trounce JR, Macdonald DM. Bullous pyoderma gangrenosum and multiple myeloma. Br J Dermatol 1984; 110: 227-230.
18. Imhof JW, Vleugels Schutter GJN, Hart HC, et al. Monoclonal gammopathy (IgG) and chronic ulcerative dermatitis (phagedenic pyoderma). Acta Med Scand 1969; 186:289-292.
19. Zaabel M. Pyoderma gagraenosum mit IgG-Paraproteinämie bei Plasmozytom. Hautarzt 1976; 27:603-605.
20. Moller H, Waldenstrom JG, Zettervall O. Pyoderma gangraenosum (dermatitis ulcerosa) and monoclonal (IgA) globulin healed after melphalan treatment. Case report and review of the literature. Acta Med Scand 1978; 203:293-296.
21. Cowan MA. Ulceration of the skin in multiple myeloma. Brit J Dermatol 1961; 73:415-418.
22. Kresbach G. Pyoderma gangraenosum - Dermatitis ulcerosa. Z Haut Geschl Krankh 1971; 46:292-293.
23. Duperrat B, Puissant A, David V, et al. Pyodermite phagedenique avec IgA monoclonale et plasmocytome osseux isolé. Bull Soc Fr Derm Syph 1972; 79:615-616.
24. Kyle RA. Monoclonal gammopathy of undetermined significance. Am J Med 1978; 64:814-826.
25. Longo DL. Plasma cell disorders. In: Isselbacher KJ, Martin JB, Braunwald E, et al, eds. Harrison's principles of internal medicine. New York: McGraw Hill, 1994:1618-1625.
26. Jones RR. Cutaneous manifestations of paraproteinemia. Part II. Br J Dermatol 1981; 104:209-220.
27. Van Epps DE, Williams RL. Suppression of leucocyte chemotaxis by human IgA myeloma components. J Exp Med 1976; 144:1227-1242.
28. Norgaard O. Three cases of multiple myeloma in which the preclinical asyptomatic phases persisted throughout 15-24 years. Br J Cancer 1971; 25:417-422.